Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Laura Bukavina, MD, MPH, MSc
- 전화번호: (216) 444-6043
- 이메일: bukavil2@ccf.org
연구 연락처 백업
- 이름: Myra Krnac
- 전화번호: (216)444-1047
- 이메일: krnacm@ccf.org
연구 장소
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- Cleveland Clinic Foundation
-
연락하다:
- Laura Bukavina, MD, MPH, MSc
- 전화번호: (216) 444-6043
- 이메일: bukavil2@ccf.org
-
수석 연구원:
- Laura Bukavina, MD, MPH, MSc
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
- Planned for radical cystectomy with curative intent.
- Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Adequate organ function as defined by standard laboratory criteria.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
- Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
- Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
- Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ctDNA-negative MIBC
There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments. |
Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence free survival (RFS)
기간: 2 years
|
RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first. |
2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS)
기간: at 2 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 2 years
|
|
Overall survival
기간: at 5 years
|
Overall survival is defined as the duration of time from the start of treatment to time of death from any cause. |
at 5 years
|
|
Rate of pathological complete response (pCR)
기간: at day 0
|
To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy. |
at day 0
|
|
Rates of surgical morbidity
기간: up to 4 weeks
|
To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Rates of complications
기간: up to 4 weeks
|
To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy. |
up to 4 weeks
|
|
Positive predictive value
기간: days -42 to 0
|
To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
|
Negative predictive value
기간: days -42 to 0
|
To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement |
days -42 to 0
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CASE9826
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
There is not currently an intention or plan to share IPD
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .